The ACTIVE I Investigators: Irbesartan in Individuals with Atrial Fibrillation The most typical risk factor for the development of atrial fibrillation is hypertension,1 and two common complications in atrial fibrillation are stroke and heart failure, both which are related to elevated blood pressure Diprolene.eu .2 Randomized trials of blood-pressure reduction have shown a reduced threat of stroke and heart failure in populations without atrial fibrillation.3-6 Nevertheless, a similar relationship has yet to be shown in sufferers with atrial fibrillation, and data from trials of blood-pressure decrease in patients with atrial fibrillation are lacking.7-9 In the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events , patients with atrial fibrillation who have been already enrolled into two large parallel trials evaluating clopidogrel plus aspirin11,12 underwent another randomization, to placebo or irbesartan.
The remaining intraocular pressure was extremely elevated at 44 mm Hg . Slit-lamp examination of the left attention showed conjunctival injection, mild corneal edema, uncommon nongranulomatous keratic precipitates, and grade 1+ leukocytes and protein in the anterior chamber . Examination of the anterior chamber with gonioscopy indicated no signs of angle closure. Dilated funduscopic examination showed stable chorioretinal marks in both eyes without other signs of ocular inflammation. He received a medical diagnosis of anterior uveitis and ocular hypertension in the left eye. Treatment was started with eyedrops containing 1 percent prednisolone acetate four situations daily and with ocular hypotensive agents which includes acetazolamide , eyedrops containing 0.2 percent brimonidine twice daily, and eyedrops containing 2 percent dorzolamide and 0.5 percent timolol twice daily.